Kiriyama A, Kimura S, Yamashita S
Pharmacol Res Perspect. 2024; 12(4):e1249.
PMID: 39017590
PMC: 11253705.
DOI: 10.1002/prp2.1249.
Wu H, Lam T, Shum T, Tsai T, Chiou J
Hypertens Res. 2021; 45(2):270-282.
PMID: 34857899
PMC: 8766282.
DOI: 10.1038/s41440-021-00796-x.
Rasool M, Ali S, Khalid S, Khalid R, Majeed A, Imran I
Sci Rep. 2021; 11(1):8589.
PMID: 33883647
PMC: 8060346.
DOI: 10.1038/s41598-021-88154-2.
Skaga E, Skaga I, Grieg Z, Sandberg C, Langmoen I, Vik-Mo E
J Cancer Res Clin Oncol. 2019; 145(6):1495-1507.
PMID: 31028540
PMC: 6527541.
DOI: 10.1007/s00432-019-02920-4.
Yang T, Aquino V, Lobaton G, Li H, Colon-Perez L, Goel R
J Am Heart Assoc. 2019; 8(4):e010721.
PMID: 30755073
PMC: 6405665.
DOI: 10.1161/JAHA.118.010721.
The effect of chronic renal failure on drug metabolism and transport.
Dreisbach A, Lertora J
Expert Opin Drug Metab Toxicol. 2008; 4(8):1065-74.
PMID: 18680441
PMC: 2745294.
DOI: 10.1517/17425255.4.8.1065.
Clinical pharmacokinetics of vasodilators. Part I.
Kirsten R, Nelson K, Kirsten D, Heintz B
Clin Pharmacokinet. 1998; 34(6):457-82.
PMID: 9646008
DOI: 10.2165/00003088-199834060-00003.
Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.
Plosker G, McTavish D
Drugs Aging. 1995; 7(3):226-53.
PMID: 8535052
DOI: 10.2165/00002512-199507030-00007.
Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
Hoyer J, Schulte K, Lenz T
Clin Pharmacokinet. 1993; 24(3):230-54.
PMID: 8462229
DOI: 10.2165/00003088-199324030-00005.
Pharmacokinetic drug interactions with ACE inhibitors.
Shionoiri H
Clin Pharmacokinet. 1993; 25(1):20-58.
PMID: 8354016
DOI: 10.2165/00003088-199325010-00003.
Choosing the right ACE inhibitor. A guide to selection.
Leonetti G, Cuspidi C
Drugs. 1995; 49(4):516-35.
PMID: 7789286
DOI: 10.2165/00003495-199549040-00003.
Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.
Heel R, Brogden R, Speight T, Avery G
Drugs. 1980; 20(6):409-52.
PMID: 7009133
DOI: 10.2165/00003495-198020060-00001.
Maintenance of the antihypertensive efficacy of captopril despite consistent reduction in daily dosage.
Mimran A, Jover B
Br J Clin Pharmacol. 1982; 14 Suppl 2:81S-85S.
PMID: 6753909
PMC: 1427506.
DOI: 10.1111/j.1365-2125.1982.tb02062.x.
Low dose captopril in the treatment of severe refractory hypertension associated with renal failure.
Bell G, Watson M, Doig A, Muir A, Winney R
Postgrad Med J. 1982; 58(681):419-21.
PMID: 6750588
PMC: 2426495.
DOI: 10.1136/pgmj.58.681.419.
Vasodilators.
Zsoter T
Can Med Assoc J. 1983; 129(5):424-8, 432.
PMID: 6349763
PMC: 1875176.
Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs.
Abe Y, Okahara T, Miura K, Yukimura T, Takada T, Iwatani T
Naunyn Schmiedebergs Arch Pharmacol. 1984; 325(4):356-9.
PMID: 6328337
DOI: 10.1007/BF00504381.
Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.
Richer C, Giroux B, Plouin P, Maarek B, Giudicelli J
Br J Clin Pharmacol. 1984; 17(3):243-50.
PMID: 6324834
PMC: 1463370.
DOI: 10.1111/j.1365-2125.1984.tb02338.x.
Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.
van Zwieten P, de Jonge A, Timmermans P
Pharm Weekbl Sci. 1983; 5(5):197-204.
PMID: 6316248
DOI: 10.1007/BF02332943.
Concentration effect modelling with converting enzyme inhibitors in man.
Kelman A, Reid J, Millar J
Br J Clin Pharmacol. 1983; 15(4):506-7.
PMID: 6303376
PMC: 1427814.
DOI: 10.1111/j.1365-2125.1983.tb01542.x.
Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure.
Ricci S, Zaniol P, Teglio V, Baraldi P, Mattioli G
Br J Clin Pharmacol. 1982; 14 Suppl 2:209S-215S.
PMID: 6291564
PMC: 1427523.
DOI: 10.1111/j.1365-2125.1982.tb02079.x.